Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study

American Journal of Gastroenterology

Volumn 96, Issue 9 SUPPL., 2001, Pages 2711-2717

  Abdelmalek, Manal F ^a,b   Angulo, Paul ^a   Jorgensen, Roberta A ^a   Sylvestre, Pamela B ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; STEATOSIS;

ADULT; BETAINE; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; LIPOTROPIC AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 0034834208     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02691-0     Document Type: Article

References (45)

1. Nonalcoholic steatohepatitis. Mayo Clinic experience with hitherto unnamed disease
2. Fatty liver disease in morbid obesity
3. Two cases in the spectrum of nonalcoholic steatohepatitis
4. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
5. Nonalcoholic steatohepatitis: A study of 49 patients
6. Fasting in obesity: Another cause of liver injury with alcoholic hyaline?
7. Liver morphology and function tests in obesity and during total starvation
8. Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration
9. Betaine therapy in homocystinemia
10. Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions
11. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients for up to 21 years
12. Nonalcoholic steatohepatitis: A study of 49 patients
13. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass
14. Liver morphology and function tests in obesity and during starvation
15. Treatment of obesity-induced steatobepatitis with vitamin E
16. Dietary lechitin, antioxidant, and vitamin B complex (LAB) decrease hepatic steatosis on patients with nonalcoholic steatohepatitis
17. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
18. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
19. Pilot study of troglitazone (resulin) for nonalcoholic steatohepatitis
20. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical trial
21. Homocystinuria: The effects of betaine in the treatment of patients not responsive to pyridoxine
22. The use of betaine for the treatment of homocystinuria
23. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency
24. Betaine for homocystinuria
25. Plasma total homocysteine levels are higher in nonalcoholic steatohepatitis
26. Laboratory predictors of non-alcoholic steatohepatitis (NASH)
27. Involvement of CYP2E1, and CYP4A in the pathogenesis of experimental nonalcholic steatohepatitis, insights from studies in CYP2E1 knockout mice
28. Cytokine profiles in NASH: Effects of diet, exercise, and vitamin E
29. Activity of the mitochondrial respirtatory chain enzymes is decreased in liver of patients with nonalcoholic steatohepatitis
30. Evidence supporting increased basal oxidative stress and impaired antioxidant defenses in fatty livers
31. Oxidative stress in hepatic fibrogenesis: Implications from a nutritional model of nonalcoholic steatohepatitis
32. Choline
33. Identification and properties of two methytransferases in conversion of phosphatidylethanolamine to phosphatidylcholine
34. Phospholipid methylation and biological signal transmission
35. 5-methyltetrahydrofolate in the rat
36. Effect of prolonged ethanol intake. Production of fatty liver despite adequate diets
37. Study of agents for the prevention of the fatty liver produced by prolonged alcohol intake
38. S-adenosylmethionine attenuates alcohol induced liver injury in the baboon
39. Liver choline oxidase activity in man and several species of animals
40. Effects of oral S-adenosyl-methionine on hepatic glutathionine in patients with liver disease
41. S-adenosylmethionine: A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism
42. Elevation of serum aminotransferases during S adenosylmethionine treatment for possible drug-induced cholestasis
43. Methionine, choline, and betaine in oral solution for the treatment of alcoholic fatty liver: Results of a multicenter randomized double-blind clinical trial